The global transplant diagnostics market is poised for remarkable growth, with projections indicating a robust CAGR of 7.40% and revenues expected to surpass USD 6.4 billion by 2028. This growth ...
Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company poised to enter a Phase 3 study of ST-62516 (trimetazidine) to reduce the risk of cardiorenal complications after PCI, ...